brivoligide (AYX1) / Merck (MSD) - LARVOL DELTA

"My colleagues are great; adding their own decorations! https://t.co/7ayxG1Tczm" (@Ddrekonja)

MicroRNA-124-3p attenuates the development of nerve injury-induced neuropathic pain by targeting early growth response 1 in the dorsal root ganglia and spinal dorsal horn. (PubMed, J Neurochem) - "injection of Egr1 decoy AYX1 inhibited the expression of Egr1 and attenuated the neuropathic pain-like hypersensitivity following SNL...Together, our results suggest that the miR-124-3p-regulated Egr1 expression in the DRG and dorsal horn contributes to the development of neuropathic pain. Targeting miR-124-3p might be a promising therapeutic strategy in the treatment of chronic pain."

Journal • Immunology • Neuralgia • Pain • Peripheral Neuropathic Pain • EGR1

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Adynxx, Inc.; N=122 ➔ 0; Trial completion date: Jun 2020 ➔ Feb 2022; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Jun 2020 ➔ Jan 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Anesthesia • Musculoskeletal Diseases • Orthopedics • Pain

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Adynxx, Inc.; N=126 ➔ 0; Trial completion date: Dec 2020 ➔ Feb 2022; Initiation date: Dec 2019 ➔ Jan 2021; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Dec 2020 ➔ Jan 2022

Clinical • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Anesthesia • Pain

Cubist announces fourth quarter/full-year 2013 revenues; provides pipeline update (Businesswire) - "In February 2013, Cubist entered into an option agreement under which Cubist has the exclusive right to acquire Adynxx, Inc. following receipt of data from Adynxx’s Phase 2 trial for...AYX1...Following review of the Phase 2 data, Cubist has decided to not exercise its right to acquire Adynxx. While AYX1 was well-tolerated in this trial and the observed clinical response may warrant continued exploration, the magnitude of the clinical response did not meet Cubist’s exercise criteria."

Pipeline update • Pain

"Duffy, Alonso Ancira 🤔💺 #كتابات_منيره #tele2019 #29AEC https://t.co/AyX1hIGoFk" (@ff3247)

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores (clinicaltrials.gov) - P2; N=126; Not yet recruiting; Sponsor: Adynxx, Inc.

Clinical • New P2 trial

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores (clinicaltrials.gov) - P2; N=122; Not yet recruiting; Sponsor: Adynxx, Inc.; Trial completion date: Feb 2020 ➔ Jun 2020; Initiation date: May 2019 ➔ Oct 2019; Trial primary completion date: Feb 2020 ➔ Jun 2020

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores (clinicaltrials.gov) - P2; N=122; Not yet recruiting; Sponsor: Adynxx, Inc.

Clinical • New P2 trial